2023-09-012024-08-312024-08-31false12137804KENSINGTON MEDISPA LTD2025-05-12falseiso4217:GBPxbrli:pure121378042023-09-01121378042024-08-31121378042023-09-012024-08-31121378042022-09-01121378042023-08-31121378042022-09-012023-08-3112137804bus:SmallEntities2023-09-012024-08-3112137804bus:AuditExempt-NoAccountantsReport2023-09-012024-08-3112137804bus:FullAccounts2023-09-012024-08-3112137804bus:PrivateLimitedCompanyLtd2023-09-012024-08-3112137804core:WithinOneYear2024-08-3112137804core:AfterOneYear2024-08-3112137804core:WithinOneYear2023-08-3112137804core:AfterOneYear2023-08-3112137804core:ShareCapital2024-08-3112137804core:SharePremium2024-08-3112137804core:RevaluationReserve2024-08-3112137804core:OtherReservesSubtotal2024-08-3112137804core:RetainedEarningsAccumulatedLosses2024-08-3112137804core:ShareCapital2023-08-3112137804core:SharePremium2023-08-3112137804core:RevaluationReserve2023-08-3112137804core:OtherReservesSubtotal2023-08-3112137804core:RetainedEarningsAccumulatedLosses2023-08-3112137804core:LandBuildings2024-08-3112137804core:PlantMachinery2024-08-3112137804core:Vehicles2024-08-3112137804core:FurnitureFittings2024-08-3112137804core:OfficeEquipment2024-08-3112137804core:NetGoodwill2024-08-3112137804core:IntangibleAssetsOtherThanGoodwill2024-08-3112137804core:ListedExchangeTraded2024-08-3112137804core:UnlistedNon-exchangeTraded2024-08-3112137804core:LandBuildings2023-08-3112137804core:PlantMachinery2023-08-3112137804core:Vehicles2023-08-3112137804core:FurnitureFittings2023-08-3112137804core:OfficeEquipment2023-08-3112137804core:NetGoodwill2023-08-3112137804core:IntangibleAssetsOtherThanGoodwill2023-08-3112137804core:ListedExchangeTraded2023-08-3112137804core:UnlistedNon-exchangeTraded2023-08-3112137804core:LandBuildings2023-09-012024-08-3112137804core:PlantMachinery2023-09-012024-08-3112137804core:Vehicles2023-09-012024-08-3112137804core:FurnitureFittings2023-09-012024-08-3112137804core:OfficeEquipment2023-09-012024-08-3112137804core:NetGoodwill2023-09-012024-08-3112137804core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3112137804core:ListedExchangeTraded2023-09-012024-08-3112137804core:UnlistedNon-exchangeTraded2023-09-012024-08-3112137804core:MoreThanFiveYears2023-09-012024-08-3112137804core:Non-currentFinancialInstruments2024-08-3112137804core:Non-currentFinancialInstruments2023-08-3112137804dpl:CostSales2023-09-012024-08-3112137804dpl:DistributionCosts2023-09-012024-08-3112137804core:LandBuildings2023-09-012024-08-3112137804core:PlantMachinery2023-09-012024-08-3112137804core:Vehicles2023-09-012024-08-3112137804core:FurnitureFittings2023-09-012024-08-3112137804core:OfficeEquipment2023-09-012024-08-3112137804dpl:AdministrativeExpenses2023-09-012024-08-3112137804core:NetGoodwill2023-09-012024-08-3112137804core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3112137804dpl:GroupUndertakings2023-09-012024-08-3112137804dpl:ParticipatingInterests2023-09-012024-08-3112137804dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3112137804core:ListedExchangeTraded2023-09-012024-08-3112137804dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3112137804core:UnlistedNon-exchangeTraded2023-09-012024-08-3112137804dpl:CostSales2022-09-012023-08-3112137804dpl:DistributionCosts2022-09-012023-08-3112137804core:LandBuildings2022-09-012023-08-3112137804core:PlantMachinery2022-09-012023-08-3112137804core:Vehicles2022-09-012023-08-3112137804core:FurnitureFittings2022-09-012023-08-3112137804core:OfficeEquipment2022-09-012023-08-3112137804dpl:AdministrativeExpenses2022-09-012023-08-3112137804core:NetGoodwill2022-09-012023-08-3112137804core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3112137804dpl:GroupUndertakings2022-09-012023-08-3112137804dpl:ParticipatingInterests2022-09-012023-08-3112137804dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3112137804core:ListedExchangeTraded2022-09-012023-08-3112137804dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3112137804core:UnlistedNon-exchangeTraded2022-09-012023-08-3112137804core:NetGoodwill2024-08-3112137804core:IntangibleAssetsOtherThanGoodwill2024-08-3112137804core:LandBuildings2024-08-3112137804core:PlantMachinery2024-08-3112137804core:Vehicles2024-08-3112137804core:FurnitureFittings2024-08-3112137804core:OfficeEquipment2024-08-3112137804core:AfterOneYear2024-08-3112137804core:WithinOneYear2024-08-3112137804core:ListedExchangeTraded2024-08-3112137804core:UnlistedNon-exchangeTraded2024-08-3112137804core:ShareCapital2024-08-3112137804core:SharePremium2024-08-3112137804core:RevaluationReserve2024-08-3112137804core:OtherReservesSubtotal2024-08-3112137804core:RetainedEarningsAccumulatedLosses2024-08-3112137804core:NetGoodwill2023-08-3112137804core:IntangibleAssetsOtherThanGoodwill2023-08-3112137804core:LandBuildings2023-08-3112137804core:PlantMachinery2023-08-3112137804core:Vehicles2023-08-3112137804core:FurnitureFittings2023-08-3112137804core:OfficeEquipment2023-08-3112137804core:AfterOneYear2023-08-3112137804core:WithinOneYear2023-08-3112137804core:ListedExchangeTraded2023-08-3112137804core:UnlistedNon-exchangeTraded2023-08-3112137804core:ShareCapital2023-08-3112137804core:SharePremium2023-08-3112137804core:RevaluationReserve2023-08-3112137804core:OtherReservesSubtotal2023-08-3112137804core:RetainedEarningsAccumulatedLosses2023-08-3112137804core:NetGoodwill2022-09-0112137804core:IntangibleAssetsOtherThanGoodwill2022-09-0112137804core:LandBuildings2022-09-0112137804core:PlantMachinery2022-09-0112137804core:Vehicles2022-09-0112137804core:FurnitureFittings2022-09-0112137804core:OfficeEquipment2022-09-0112137804core:AfterOneYear2022-09-0112137804core:WithinOneYear2022-09-0112137804core:ListedExchangeTraded2022-09-0112137804core:UnlistedNon-exchangeTraded2022-09-0112137804core:ShareCapital2022-09-0112137804core:SharePremium2022-09-0112137804core:RevaluationReserve2022-09-0112137804core:OtherReservesSubtotal2022-09-0112137804core:RetainedEarningsAccumulatedLosses2022-09-0112137804core:AfterOneYear2023-09-012024-08-3112137804core:WithinOneYear2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:CostValuation2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3112137804core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3112137804core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3112137804core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3112137804core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3112137804core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3112137804core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3112137804core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3112137804core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3112137804core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3112137804core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3112137804core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3112137804core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3112137804core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3112137804core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3112137804core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3112137804core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3112137804core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3112137804core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3112137804bus:Director12023-09-012024-08-3112137804core:FurnitureFittingsToolsEquipment2023-08-3112137804core:FurnitureFittingsToolsEquipment2023-09-012024-08-3112137804core:FurnitureFittingsToolsEquipment2024-08-31

KENSINGTON MEDISPA LTD

Registered Number
12137804
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2024

KENSINGTON MEDISPA LTD
Company Information
for the year from 1 September 2023 to 31 August 2024

Director

BASUDEV, Natasha

Registered Address

132 Bath Road
Hounslow
TW3 3ET

Registered Number

12137804 (England and Wales)
KENSINGTON MEDISPA LTD
Balance Sheet as at
31 August 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets357,60276,753
57,60276,753
Current assets
Stocks44,0004,000
Debtors550,04149,592
Cash at bank and on hand51,19667,879
105,237121,471
Creditors amounts falling due within one year6(137,738)(174,711)
Net current assets (liabilities)(32,501)(53,240)
Total assets less current liabilities25,10123,513
Creditors amounts falling due after one year7(59,715)(70,625)
Provisions for liabilities9(14,400)(19,188)
Net assets(49,014)(66,300)
Capital and reserves
Called up share capital1010
Profit and loss account(49,024)(66,310)
Shareholders' funds(49,014)(66,300)
The financial statements were approved and authorised for issue by the Director on 12 May 2025, and are signed on its behalf by:
BASUDEV, Natasha
Director
Registered Company No. 12137804
KENSINGTON MEDISPA LTD
Notes to the Financial Statements
for the year ended 31 August 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery25
Fixtures and fittings25
Vehicles25
Office Equipment25
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20242023
Average number of employees during the year11
3.Tangible fixed assets

Plant & machinery

Vehicles

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 September 2370,57472,61310,4254,070157,682
Additions--48-48
At 31 August 2470,57472,61310,4734,070157,730
Depreciation and impairment
At 01 September 2338,48734,4495,9792,01480,929
Charge for year8,0219,5411,12351419,199
At 31 August 2446,50843,9907,1022,528100,128
Net book value
At 31 August 2424,06628,6233,3711,54257,602
At 31 August 2332,08738,1644,4462,05676,753
4.Stocks

2024

2023

££
Finished goods4,0004,000
Total4,0004,000
5.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables1,8205,784
Other debtors45,23142,805
Prepayments and accrued income2,9901,003
Total50,04149,592
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
6.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables4,9752,283
Bank borrowings and overdrafts6,7306,730
Taxation and social security7,8426,743
Finance lease and HP contracts4,1814,181
Other creditors108,534148,128
Accrued liabilities and deferred income5,4766,646
Total137,738174,711
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
7.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts36,06042,790
Other creditors23,65527,835
Total59,71570,625
8.Obligations under finance leases

2024

2023

££
Finance lease and HP contracts23,65427,835
9.Provisions for liabilities

2024

2023

££
Net deferred tax liability (asset)14,40019,188
Total14,40019,188
10.Guarantees provided on behalf of directors
The credit balance of £16,469 (2023: £18,860) relates to director.